Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Kroschinsky F, Middeke JM, Janz M, Lenz G, Witzens-Harig M, Bouabdallah R, La Rosée P, Viardot A, Salles G, Kim SJ, Kim TM, Ottmann O, Chromik J, Quinson AM, von Wangenheim U, Burkard U, Berk A, Schmitz N. Kroschinsky F, et al. Among authors: burkard u. Invest New Drugs. 2020 Oct;38(5):1472-1482. doi: 10.1007/s10637-020-00916-3. Epub 2020 Mar 14. Invest New Drugs. 2020. PMID: 32172489 Free PMC article. Clinical Trial.
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Kroschinsky F, Middeke JM, Janz M, Lenz G, Witzens-Harig M, Bouabdallah R, La Rosée P, Viardot A, Salles G, Kim SJ, Kim TM, Ottmann O, Chromik J, Quinson AM, von Wangenheim U, Burkard U, Berk A, Schmitz N. Kroschinsky F, et al. Among authors: burkard u. Invest New Drugs. 2021 Feb;39(1):283-284. doi: 10.1007/s10637-020-00949-8. Invest New Drugs. 2021. PMID: 32474843 Free PMC article. No abstract available.
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
Kroschinsky F, Middeke JM, Janz M, Lenz G, Witzens-Harig M, Bouabdallah R, La Rosée P, Viardot A, Salles G, Kim SJ, Kim TM, Ottmann O, Chromik J, Quinson AM, von Wangenheim U, Burkard U, Berk A, Schmitz N. Kroschinsky F, et al. Among authors: burkard u. Invest New Drugs. 2021 Feb;39(1):285-286. doi: 10.1007/s10637-020-00964-9. Invest New Drugs. 2021. PMID: 32578153 Free PMC article. No abstract available.
An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia.
Fiedler W, Montesinos P, Schliemann C, Middeke J, Vasu S, Scholz CW, Esteve J, Mondal S, Rüter B, Burkard U, Osswald A, Blum W. Fiedler W, et al. Among authors: burkard u. Haematologica. 2022 Dec 1;107(12):2977-2982. doi: 10.3324/haematol.2022.281128. Haematologica. 2022. PMID: 36005556 Free PMC article. Clinical Trial. No abstract available.
A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia.
Vasu S, Altman JK, Uy GL, Tallman MS, Gojo I, Lozanski G, Burkard U, Osswald A, James P, Rüter B, Blum W. Vasu S, et al. Among authors: burkard u. Haematologica. 2022 Mar 1;107(3):770-773. doi: 10.3324/haematol.2020.274118. Haematologica. 2022. PMID: 34854276 Free PMC article. Clinical Trial. No abstract available.
The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [14C]-BI 425809 in Healthy Males.
Burkard U, Desch M, Shatillo Y, Wunderlich G, Mack SR, Schlecker C, Teitelbaum AM, Liu P, Chan TS. Burkard U, et al. Clin Drug Investig. 2022 Jan;42(1):87-99. doi: 10.1007/s40261-021-01111-9. Epub 2021 Dec 22. Clin Drug Investig. 2022. PMID: 34936055 Free PMC article. Clinical Trial.
A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome.
Komrokji RS, Carraway HE, Germing U, Wermke M, Zeidan AM, Fu E, Rüter B, Burkard U, Osswald A, Foran JM. Komrokji RS, et al. Among authors: burkard u. Haematologica. 2022 Nov 1;107(11):2742-2747. doi: 10.3324/haematol.2021.280500. Haematologica. 2022. PMID: 35734924 Free PMC article. Clinical Trial. No abstract available.
Correction to: The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [14C]‑BI 425809 in Healthy Males.
Burkard U, Desch M, Shatillo Y, Wunderlich G, Mack SR, Schlecker C, Teitelbaum AM, Liu P, Chan TS. Burkard U, et al. Clin Drug Investig. 2022 Apr;42(4):375. doi: 10.1007/s40261-022-01134-w. Clin Drug Investig. 2022. PMID: 35286627 Free PMC article. No abstract available.
The RNA component of RNase P in Schizosaccharomyces species.
Zimmerly S, Gamulin V, Burkard U, Söll D. Zimmerly S, et al. Among authors: burkard u. FEBS Lett. 1990 Oct 1;271(1-2):189-93. doi: 10.1016/0014-5793(90)80403-6. FEBS Lett. 1990. PMID: 2226803 Free article.
14 results